HGH Fragment 176-191

HGH Fragment 176-191 is reported as the 176-191 C-terminal segment of human growth hormone associated with lipolytic activity. The source describes lab and animal findings in which the fragment increases glycerol release and fat oxidation, while appearing not to bind the growth-hormone receptor. Reported differentiators from full growth hormone include no IGF-1 rise, no tissue-growth promotion, and no impairment of glucose handling. The source also notes possible beta-3 adrenergic signaling in fat tissue, but says the human mechanism is not fully established.

The source reports promising animal findings but weaker clinical efficacy. In obese mice, AOD-9604 and growth hormone were described as reducing body-weight gain and increasing fat oxidation, with AOD-9604 not showing the glucose concerns associated with full growth hormone. A small 12-week phase 2 study is reported to have shown about 2.8 kg loss in the 1 mg group versus 0.8 kg with placebo. A larger phase 2b study of roughly 500 obese adults over 24 weeks reportedly did not demonstrate a significant weight-loss benefit over placebo, after which obesity development was abandoned. Safety findings are described across about six trials and roughly 900 participants, with tolerability similar to placebo and no IGF-1 or glucose effects reported.